Status:
COMPLETED
Trial for Treatment of Adult Patients With Standard Risk Acute Lymphoblastic Leukemia With Chemotherapy and Rituximab
Lead Sponsor:
Johann Wolfgang Goethe University Hospital
Conditions:
Adult Acute Lymphocytic Leukemia
Eligibility:
All Genders
15-65 years
Phase:
PHASE4
Brief Summary
The study evaluates the efficacy and tolerability of an intensified induction and consolidation therapy in combination with rituximab in CD20 positive standard risk patients. Thereafter patients recei...
Eligibility Criteria
Inclusion
- B-precursor ALL (common / pre B-ALL)
- Standard risk
- CD20 expression \>20%
- Ph/BCR-ABL negative
- Age 15-65 years (55-65 if biologically younger)
- Written informed consent
Exclusion
- Severe complications due to leukemia or secondary illnesses
- Late relapse of childhood ALL
- Cytostatic pretreatment
- Pregnancy
- Severe psychiatric illness or other circumstances which may compromise cooperation of the patient or informed consent
- Known severe allergy to foreign proteins
Key Trial Info
Start Date :
April 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2009
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00199004
Start Date
April 1 2004
End Date
March 1 2009
Last Update
August 23 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital of Frankfurt, Medical Dept. II
Frankfurt, Germany, 60590